BioVie Inc (NASDAQ:BIVI) has announced additional preliminary findings from the Parkinson’s disease Phase 2 trial of its drug NE3107, showing a significant improvement over the current standard of care (SOC).
The preliminary findings show that significantly more patients treated with NE3107 were considered to be in what’s called the “on” state of muscle control in the morning after withholding their usual (SOC) for at least 8 hours before taking their usual morning Parkinson’s medications when compared to a placebo.
Parkinson’s patients typically have rigid muscles and difficulty getting out of bed in the morning, which is referred to as the muscles being in an “off state.” Conversely, having sufficient muscle control is the "on" state, which is crucial for better movement and stability.
READ: BioVie announces completion of patient enrollment in Phase 3 trial assessing NE3107 in Alzheimer's
The data impressed Anthony Lang, the Jack Clark Chair for Parkinson’s disease research at the University of Toronto, who was not involved with the trial.
“Biovie's Phase 2 data is encouraging,” Lang said in a statement. “Morning ‘off’ symptoms cause significant impairment of movement and disability for patients with Parkinson’s Disease. A potential treatment that can address this symptom is an important therapeutic need.”
Based on these results, BioVie is preparing to launch a Phase 3 potential pivotal trials to continue developing NE3107 in Parkinson’s disease.
BioVie is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In neurodegenerative disease, the company’s drug candidate NE3107 inhibits inflammatory activation that leads to neuroinflammation and insulin resistance, but not their homeostatic functions like insulin signaling, neuron growth and survival. Both are drivers of Alzheimer’s and Parkinson’s diseases.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel